Glasdegib

What is Glasdegib?

Glasdegib is an oral medication primarily used in the treatment of certain types of cancer. Marketed under the brand name Daurismo, it belongs to a class of drugs known as hedgehog pathway inhibitors. Its main application is in the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.

AML is a rapidly progressing cancer of the blood and bone marrow, characterized by the uncontrolled growth of abnormal myeloid cells. Glasdegib offers a targeted approach by interfering with specific cellular pathways crucial for cancer cell survival and proliferation. It is a small molecule inhibitor, meaning it can penetrate cells to disrupt specific molecular targets, providing a vital therapeutic option for a vulnerable patient population.

How Does it Work?

The mechanism of action for Glasdegib revolves around its ability to inhibit the Hedgehog signaling pathway. This pathway plays a critical role in embryonic development and tissue maintenance in adults. However, in certain cancers, including AML, this pathway can become aberrantly activated, leading to uncontrolled cell growth, survival, and differentiation.

Glasdegib specifically acts as a potent and selective Smoothened (SMO) inhibitor. Smoothened is a G protein-coupled receptor that is a key component of the Hedgehog pathway. When Glasdegib binds to and inhibits SMO, it disrupts the downstream signaling cascade that would otherwise promote the expression of genes involved in cell proliferation and survival. By blocking this crucial pathway, Glasdegib helps to reduce the proliferation of AML cells and induce their differentiation or apoptosis (programmed cell death), thereby slowing the progression of the disease.

Medical Uses

Glasdegib's primary medical use is for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults. It is specifically indicated for patients who meet certain criteria:

• Adults aged 75 years or older.
• Adults who have comorbidities that make them ineligible for standard intensive induction chemotherapy.

It is important to note that Glasdegib is typically used in combination with low-dose cytarabine (LDAC), another chemotherapy agent. This combination therapy aims to enhance the overall anti-leukemic effect in these specific patient populations, offering a less intensive but effective treatment option when aggressive chemotherapy is not feasible. The decision to use Glasdegib is made by a healthcare professional based on the patient's individual health status and disease characteristics.

Dosage

The recommended dosage of Glasdegib is 100 mg taken orally once daily. It can be taken with or without food. Patients should take the medication at approximately the same time each day to maintain consistent drug levels in the body.

Treatment with Glasdegib is usually continued until disease progression or until unacceptable toxicity occurs. The healthcare provider will regularly monitor the patient's response to treatment and assess for any adverse effects. It is crucial for patients to adhere to the prescribed dosage and not to adjust it without consulting their doctor. If a dose is missed, patients should take it as soon as they remember, unless it is almost time for the next dose, in which case the missed dose should be skipped.

Side Effects

Like all medications, Glasdegib can cause side effects. Some of the common side effects include:

• Nausea and vomiting
• Fatigue and asthenia
• Musculoskeletal pain
• Constipation or diarrhea
• Rash
• Dysgeusia (taste disturbance)
• Decreased appetite
• Peripheral neuropathy

More serious side effects, though less common, can occur. These may include:

• Embryo-fetal toxicity: Glasdegib can cause severe birth defects or death to an unborn baby. Women of childbearing potential must use effective contraception during treatment and for at least 30 days after the last dose. Men with female partners of childbearing potential must use effective contraception during treatment and for at least 30 days after the last dose.
• QT prolongation: This is a heart rhythm disorder that can lead to serious, life-threatening arrhythmias. Regular ECG monitoring may be required.
• Rhabdomyolysis: A rare but serious condition involving muscle breakdown, which can lead to kidney damage.
• Hematologic toxicities: While treating AML, Glasdegib can also affect healthy blood cells, leading to anemia, thrombocytopenia, or neutropenia.

Patients should report any new or worsening symptoms to their healthcare provider immediately.

Drug Interactions

Glasdegib is metabolized by the enzyme CYP3A and is also a substrate of P-glycoprotein (P-gp). Therefore, it can interact with other medications that affect these pathways. Key drug interactions to be aware of include:

• Strong CYP3A inhibitors: Co-administration with strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) can increase Glasdegib exposure, potentially leading to increased side effects. Dose adjustments or close monitoring may be necessary.
• Strong CYP3A inducers: Co-administration with strong CYP3A inducers (e.g., rifampin, phenytoin, St. John's Wort) can decrease Glasdegib exposure, potentially reducing its effectiveness.
• P-gp substrates: Glasdegib may increase the exposure of P-gp substrate drugs.
• Drugs that prolong the QT interval: Concurrent use with other medications known to prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, antidepressants) can increase the risk of serious cardiac arrhythmias.

It is crucial for patients to inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potentially harmful interactions.

FAQ

Can Glasdegib be used as a standalone treatment for AML?

No, Glasdegib is typically used in combination with low-dose cytarabine (LDAC) for newly diagnosed AML in the specified patient population.

Who is eligible to receive Glasdegib?

It is indicated for adults with newly diagnosed AML who are 75 years or older, or who have comorbidities that prevent them from receiving intensive induction chemotherapy.

How long will I need to take Glasdegib?

Treatment is usually continued until the disease progresses or until you experience unacceptable side effects.

What should I do if I miss a dose?

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one.

Is Glasdegib a chemotherapy drug?

While used in cancer treatment, Glasdegib is considered a targeted therapy rather than traditional chemotherapy. It specifically inhibits a molecular pathway (Hedgehog) involved in cancer growth, making it a more precise antineoplastic agent.

Products containing Glasdegib are available through trusted online pharmacies. You can browse Glasdegib-based medications at ShipperVIP or Medicenter.

Summary

Glasdegib is an important oral targeted therapy for certain adult patients with newly diagnosed acute myeloid leukemia (AML). As a hedgehog signaling pathway inhibitor, it works by blocking the Smoothened (SMO) protein, thereby disrupting cancer cell growth and survival. It is typically used in combination with low-dose cytarabine (LDAC) for older patients or those with significant comorbidities who cannot tolerate intensive chemotherapy. While effective, patients should be aware of potential side effects, including embryo-fetal toxicity and the risk of QT prolongation, and discuss all medications with their healthcare provider to manage potential drug interactions. Glasdegib represents a valuable option in the evolving landscape of AML treatment, offering a targeted approach for a specific patient population.